ZA200509521B - Modified fluorinated nucleoside analogues - Google Patents

Modified fluorinated nucleoside analogues Download PDF

Info

Publication number: ZA200509521B
Authority: ZA; South Africa
Prior art keywords: alkyl; acyl; alkenyl; alkynyl; optionally substituted
Prior art date: 2003-05-30

Application number

ZA200509521A

Other languages

English (en)

Inventor

Clark Jeremy

Original Assignee

Pharmasset Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-30

Filing date

2005-11-24

Publication date

2006-10-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33563735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200509521(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-11-24 Application filed by Pharmasset Inc filed Critical Pharmasset Inc

2006-10-25 Publication of ZA200509521B publication Critical patent/ZA200509521B/en

Links

229940127073 nucleoside analogue Drugs 0.000 title description 3
125000000217 alkyl group Chemical group 0.000 claims description 660
229910052731 fluorine Inorganic materials 0.000 claims description 232
239000002777 nucleoside Substances 0.000 claims description 153
239000003112 inhibitor Substances 0.000 claims description 101
108090000765 processed proteins & peptides Proteins 0.000 claims description 101
238000011282 treatment Methods 0.000 claims description 100
150000001875 compounds Chemical class 0.000 claims description 97
150000003839 salts Chemical class 0.000 claims description 73
102000014150 Interferons Human genes 0.000 claims description 71
108010050904 Interferons Proteins 0.000 claims description 70
229940079322 interferon Drugs 0.000 claims description 70
102000006992 Interferon-alpha Human genes 0.000 claims description 69
108010047761 Interferon-alpha Proteins 0.000 claims description 68
150000003833 nucleoside derivatives Chemical class 0.000 claims description 65
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 62
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 61
229960000329 ribavirin Drugs 0.000 claims description 57
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 57
239000003937 drug carrier Substances 0.000 claims description 56
229910052736 halogen Inorganic materials 0.000 claims description 56
150000002367 halogens Chemical class 0.000 claims description 56
-1 sulfonate ester Chemical class 0.000 claims description 56
229940123066 Polymerase inhibitor Drugs 0.000 claims description 41
IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims description 38
101710144111 Non-structural protein 3 Proteins 0.000 claims description 30
239000000203 mixture Substances 0.000 claims description 29
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 29
101800001554 RNA-directed RNA polymerase Proteins 0.000 claims description 26
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 24
108010074328 Interferon-gamma Proteins 0.000 claims description 23
102000053642 Catalytic RNA Human genes 0.000 claims description 22
108090000994 Catalytic RNA Proteins 0.000 claims description 22
102000008070 Interferon-gamma Human genes 0.000 claims description 22
108010046075 Thymosin Proteins 0.000 claims description 22
102000007501 Thymosin Human genes 0.000 claims description 22
229960003805 amantadine Drugs 0.000 claims description 22
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 22
229960003130 interferon gamma Drugs 0.000 claims description 22
108700027921 interferon tau Proteins 0.000 claims description 22
108091092562 ribozyme Proteins 0.000 claims description 22
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 21
102100040018 Interferon alpha-2 Human genes 0.000 claims description 21
108010079944 Interferon-alpha2b Proteins 0.000 claims description 21
102000003996 Interferon-beta Human genes 0.000 claims description 21
108090000467 Interferon-beta Proteins 0.000 claims description 21
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 21
FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 claims description 21
ZVSKZLHKADLHSD-UHFFFAOYSA-N benzanilide Chemical compound C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 claims description 21
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 21
FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 claims description 21
229940103893 gliotoxin Drugs 0.000 claims description 21
229930190252 gliotoxin Natural products 0.000 claims description 21
229960001388 interferon-beta Drugs 0.000 claims description 21
NAYYNDKKHOIIOD-UHFFFAOYSA-N phthalamide Chemical compound NC(=O)C1=CC=CC=C1C(N)=O NAYYNDKKHOIIOD-UHFFFAOYSA-N 0.000 claims description 21
229940031439 squalene Drugs 0.000 claims description 21
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 21
150000003548 thiazolidines Chemical class 0.000 claims description 21
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 21
208000005176 Hepatitis C Diseases 0.000 claims description 20
102000003814 Interleukin-10 Human genes 0.000 claims description 20
108090000174 Interleukin-10 Proteins 0.000 claims description 20
239000000074 antisense oligonucleotide Substances 0.000 claims description 20
238000012230 antisense oligonucleotides Methods 0.000 claims description 20
239000003613 bile acid Substances 0.000 claims description 20
108010045648 interferon omega 1 Proteins 0.000 claims description 20
229940076144 interleukin-10 Drugs 0.000 claims description 20
108091034057 RNA (poly(A)) Proteins 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 19
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 19
229940014456 mycophenolate Drugs 0.000 claims description 19
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 19
108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 18
102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 18
229940121759 Helicase inhibitor Drugs 0.000 claims description 18
102000013462 Interleukin-12 Human genes 0.000 claims description 18
108010065805 Interleukin-12 Proteins 0.000 claims description 18
229940117681 interleukin-12 Drugs 0.000 claims description 18
206010012310 Dengue fever Diseases 0.000 claims description 16
208000010710 hepatitis C virus infection Diseases 0.000 claims description 15
206010057293 West Nile viral infection Diseases 0.000 claims description 13
208000003152 Yellow Fever Diseases 0.000 claims description 11
208000025729 dengue disease Diseases 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
208000015181 infectious disease Diseases 0.000 claims description 10
125000003835 nucleoside group Chemical group 0.000 claims description 10
108060004795 Methyltransferase Proteins 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
108091005804 Peptidases Proteins 0.000 claims description 6
239000004365 Protease Substances 0.000 claims description 5
229940024606 amino acid Drugs 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 5
230000000692 anti-sense effect Effects 0.000 claims description 4
238000003786 synthesis reaction Methods 0.000 claims description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
208000001490 Dengue Diseases 0.000 claims description 2
235000001014 amino acid Nutrition 0.000 claims description 2
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
229960005486 vaccine Drugs 0.000 claims description 2
125000003342 alkenyl group Chemical group 0.000 claims 436
125000002252 acyl group Chemical group 0.000 claims 423
125000000304 alkynyl group Chemical group 0.000 claims 320
229910052794 bromium Inorganic materials 0.000 claims 264
229910052801 chlorine Inorganic materials 0.000 claims 240
229910052740 iodine Inorganic materials 0.000 claims 226
229910019142 PO4 Inorganic materials 0.000 claims 163
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 163
239000010452 phosphate Substances 0.000 claims 163
239000000651 prodrug Substances 0.000 claims 138
229940002612 prodrug Drugs 0.000 claims 138
229910052799 carbon Inorganic materials 0.000 claims 105
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 97
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 94
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 81
125000003545 alkoxy group Chemical group 0.000 claims 69
125000000547 substituted alkyl group Chemical group 0.000 claims 62
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 62
229920002554 vinyl polymer Polymers 0.000 claims 62
125000005140 aralkylsulfonyl group Chemical group 0.000 claims 49
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 49
150000001720 carbohydrates Chemical class 0.000 claims 49
239000001177 diphosphate Substances 0.000 claims 49
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 49
235000011180 diphosphates Nutrition 0.000 claims 49
238000001727 in vivo Methods 0.000 claims 49
150000002632 lipids Chemical class 0.000 claims 49
238000011321 prophylaxis Methods 0.000 claims 49
239000001226 triphosphate Substances 0.000 claims 49
235000011178 triphosphate Nutrition 0.000 claims 49
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 49
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 48
150000003904 phospholipids Chemical class 0.000 claims 48
235000012000 cholesterol Nutrition 0.000 claims 47
150000004712 monophosphates Chemical class 0.000 claims 47
150000008574 D-amino acids Chemical class 0.000 claims 45
150000008575 L-amino acids Chemical class 0.000 claims 43
125000004122 cyclic group Chemical group 0.000 claims 42
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 40
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 40
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 35
125000004426 substituted alkynyl group Chemical group 0.000 claims 35
125000000539 amino acid group Chemical group 0.000 claims 34
125000000753 cycloalkyl group Chemical group 0.000 claims 34
125000002768 hydroxyalkyl group Chemical group 0.000 claims 32
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 28
125000004093 cyano group Chemical group *C#N 0.000 claims 28
150000001345 alkine derivatives Chemical class 0.000 claims 27
125000001153 fluoro group Chemical group F* 0.000 claims 27
229910052739 hydrogen Inorganic materials 0.000 claims 27
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 26
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 25
102000015696 Interleukins Human genes 0.000 claims 21
108010063738 Interleukins Proteins 0.000 claims 21
229940096888 Beta tubulin inhibitor Drugs 0.000 claims 20
229930003427 Vitamin E Natural products 0.000 claims 20
239000003963 antioxidant agent Substances 0.000 claims 20
230000003078 antioxidant effect Effects 0.000 claims 20
235000006708 antioxidants Nutrition 0.000 claims 20
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 20
235000019165 vitamin E Nutrition 0.000 claims 20
229940046009 vitamin E Drugs 0.000 claims 20
239000011709 vitamin E Substances 0.000 claims 20
ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 claims 19
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 19
101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 19
108091034117 Oligonucleotide Proteins 0.000 claims 19
229910052760 oxygen Inorganic materials 0.000 claims 19
229910052717 sulfur Inorganic materials 0.000 claims 19
150000001556 benzimidazoles Chemical class 0.000 claims 17
229940021993 prophylactic vaccine Drugs 0.000 claims 17
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 15
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 14
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 claims 13
206010061494 Rhinovirus infection Diseases 0.000 claims 9
229910052684 Cerium Inorganic materials 0.000 claims 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
125000003118 aryl group Chemical group 0.000 claims 4
229910052757 nitrogen Inorganic materials 0.000 claims 4
125000006239 protecting group Chemical group 0.000 claims 4
125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 3
239000002253 acid Substances 0.000 claims 3
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 3
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 2
UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
230000000069 prophylactic effect Effects 0.000 claims 2
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 2
241000905957 Channa melasoma Species 0.000 claims 1
OEMCLQLAWYKPRK-OQLLNIDSSA-N N-[(E)-(5-bromo-2-hydroxyphenyl)methylideneamino]benzenesulfonamide Chemical compound Oc1ccc(Br)cc1\C=N\NS(=O)(=O)c2ccccc2 OEMCLQLAWYKPRK-OQLLNIDSSA-N 0.000 claims 1
229910002651 NO3 Inorganic materials 0.000 claims 1
101800001775 Nuclear inclusion protein A Proteins 0.000 claims 1
241000084978 Rena Species 0.000 claims 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
229930182558 Sterol Natural products 0.000 claims 1
QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
229960005261 aspartic acid Drugs 0.000 claims 1
210000000941 bile Anatomy 0.000 claims 1
229910002091 carbon monoxide Inorganic materials 0.000 claims 1
238000010511 deprotection reaction Methods 0.000 claims 1
150000002148 esters Chemical group 0.000 claims 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
229910052702 rhenium Inorganic materials 0.000 claims 1
150000003432 sterols Chemical class 0.000 claims 1
235000003702 sterols Nutrition 0.000 claims 1
241000711549 Hepacivirus C Species 0.000 description 68
241000710778 Pestivirus Species 0.000 description 17
241000700605 Viruses Species 0.000 description 16
229920002477 rna polymer Polymers 0.000 description 13
230000000694 effects Effects 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 12
241000711557 Hepacivirus Species 0.000 description 11
230000000840 anti-viral effect Effects 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 10
241000710831 Flavivirus Species 0.000 description 10
241000710781 Flaviviridae Species 0.000 description 9
230000010076 replication Effects 0.000 description 9
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
108700026244 Open Reading Frames Proteins 0.000 description 7
238000002648 combination therapy Methods 0.000 description 7
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 6
102100040019 Interferon alpha-1/13 Human genes 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
238000011160 research Methods 0.000 description 6
102000035195 Peptidases Human genes 0.000 description 5
108010076039 Polyproteins Proteins 0.000 description 5
102000012479 Serine Proteases Human genes 0.000 description 5
108010022999 Serine Proteases Proteins 0.000 description 5
101800001838 Serine protease/helicase NS3 Proteins 0.000 description 5
208000009714 Severe Dengue Diseases 0.000 description 5
201000002950 dengue hemorrhagic fever Diseases 0.000 description 5
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 5
239000000758 substrate Substances 0.000 description 5
229940021747 therapeutic vaccine Drugs 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
YJQYHFMKGAVKDP-UHFFFAOYSA-N 3-butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione Chemical compound C12=CC=CC(O)=C2C(=O)C(=O)C2=C1C=C(C(=O)CCC)C(C)=C2O YJQYHFMKGAVKDP-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
208000004576 Flaviviridae Infections Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 description 4
108020000999 Viral RNA Proteins 0.000 description 4
239000003443 antiviral agent Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000008520 organization Effects 0.000 description 4
238000012545 processing Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
241000725619 Dengue virus Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 3
101800001020 Non-structural protein 4A Proteins 0.000 description 3
108091092724 Noncoding DNA Proteins 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
241001493065 dsRNA viruses Species 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
108700008776 hepatitis C virus NS-5 Proteins 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
235000019419 proteases Nutrition 0.000 description 3
239000003001 serine protease inhibitor Substances 0.000 description 3
238000009097 single-agent therapy Methods 0.000 description 3
SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 2
YYVYAPXYZVYDHN-UHFFFAOYSA-N 9,10-phenanthroquinone Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CC=C3C2=C1 YYVYAPXYZVYDHN-UHFFFAOYSA-N 0.000 description 2
241001118702 Border disease virus Species 0.000 description 2
241001227713 Chiron Species 0.000 description 2
241000710777 Classical swine fever virus Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
206010054261 Flavivirus infection Diseases 0.000 description 2
241000531123 GB virus C Species 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
206010022004 Influenza like illness Diseases 0.000 description 2
108010005716 Interferon beta-1a Proteins 0.000 description 2
241000764238 Isis Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
101800001019 Non-structural protein 4B Proteins 0.000 description 2
101800001014 Non-structural protein 5A Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
241000228127 Penicillium griseofulvum Species 0.000 description 2
101710172711 Structural protein Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
108010078233 Thymalfasin Proteins 0.000 description 2
102000003929 Transaminases Human genes 0.000 description 2
108090000340 Transaminases Proteins 0.000 description 2
229910052770 Uranium Inorganic materials 0.000 description 2
241000710886 West Nile virus Species 0.000 description 2
JBPUGFODGPKTDW-SFHVURJKSA-N [(3s)-oxolan-3-yl] n-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate Chemical compound C=1C=C(C=2OC=NC=2)C(OC)=CC=1NC(=O)NC(C=1)=CC=CC=1CNC(=O)O[C@H]1CCOC1 JBPUGFODGPKTDW-SFHVURJKSA-N 0.000 description 2
108010080374 albuferon Proteins 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
229950000234 emricasan Drugs 0.000 description 2
206010014599 encephalitis Diseases 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
108700012707 hepatitis C virus NS3 Proteins 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
229940090438 infergen Drugs 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
108010010648 interferon alfacon-1 Proteins 0.000 description 2
244000144972 livestock Species 0.000 description 2
229940046166 oligodeoxynucleotide Drugs 0.000 description 2
229940002988 pegasys Drugs 0.000 description 2
108010092853 peginterferon alfa-2a Proteins 0.000 description 2
108010092851 peginterferon alfa-2b Proteins 0.000 description 2
229940106366 pegintron Drugs 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
229940053146 rebetol Drugs 0.000 description 2
229940038850 rebif Drugs 0.000 description 2
230000004044 response Effects 0.000 description 2
239000002342 ribonucleoside Substances 0.000 description 2
230000000405 serological effect Effects 0.000 description 2
102000013498 tau Proteins Human genes 0.000 description 2
BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 2
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 2
229960004231 thymalfasin Drugs 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 1
ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
CEHJYEXLKQVWOT-UHFFFAOYSA-N 2,4,6-trihydroxy-3-nitrobenzamide Chemical class NC(=O)C1=C(O)C=C(O)C([N+]([O-])=O)=C1O CEHJYEXLKQVWOT-UHFFFAOYSA-N 0.000 description 1
TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 description 1
108091027075 5S-rRNA precursor Proteins 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000006154 Chronic hepatitis C Diseases 0.000 description 1
102000003858 Chymases Human genes 0.000 description 1
108090000227 Chymases Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241001550206 Colla Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
229940123457 Free radical scavenger Drugs 0.000 description 1
241000414862 GBV-A-like agents Species 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
229940124683 HCV polymerase inhibitor Drugs 0.000 description 1
229940122604 HCV protease inhibitor Drugs 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
206010061192 Haemorrhagic fever Diseases 0.000 description 1
241000545744 Hirudinea Species 0.000 description 1
244000309469 Human enteric coronavirus Species 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241000710842 Japanese encephalitis virus Species 0.000 description 1
108090000265 Meprin A Proteins 0.000 description 1
102100030876 Meprin A subunit beta Human genes 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
208000004571 Pestivirus Infections Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108030002536 RNA-directed RNA polymerases Proteins 0.000 description 1
241000015473 Schizothorax griseus Species 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000187180 Streptomyces sp. Species 0.000 description 1
108090000787 Subtilisin Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102400000800 Thymosin alpha-1 Human genes 0.000 description 1
229940122429 Tubulin inhibitor Drugs 0.000 description 1
241000710772 Yellow fever virus Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 1
229950005984 cerulenin Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
PJZPDFUUXKKDNB-KNINVFKUSA-N ciluprevir Chemical compound N([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(O)=O)=O)C[C@H](C2)OC=1C2=CC=C(C=C2N=C(C=1)C=1N=C(NC(C)C)SC=1)OC)C(=O)OC1CCCC1 PJZPDFUUXKKDNB-KNINVFKUSA-N 0.000 description 1
238000004891 communication Methods 0.000 description 1
229940055354 copegus Drugs 0.000 description 1
LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
239000012039 electrophile Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000011737 fluorine Chemical group 0.000 description 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
229940125777 fusion inhibitor Drugs 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000009368 gene silencing by RNA Effects 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
235000013902 inosinic acid Nutrition 0.000 description 1
238000012739 integrated shape imaging system Methods 0.000 description 1
229940028862 interferon gamma-1b Drugs 0.000 description 1
108010042414 interferon gamma-1b Proteins 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000002547 new drug Substances 0.000 description 1
YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
230000037361 pathway Effects 0.000 description 1
208000025858 pestivirus infectious disease Diseases 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000011268 retreatment Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000004576 sand Substances 0.000 description 1
238000002821 scintillation proximity assay Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000008279 sol Substances 0.000 description 1
230000007103 stamina Effects 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000012622 synthetic inhibitor Substances 0.000 description 1
NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 1
229950006081 taribavirin Drugs 0.000 description 1
229960002935 telaprevir Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000005450 thionucleoside Substances 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229940100050 virazole Drugs 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
229940051021 yellow-fever virus Drugs 0.000 description 1
150000004799 α-ketoamides Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

ZA200509521A 2003-05-30 2005-11-24 Modified fluorinated nucleoside analogues ZA200509521B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US47436803P	2003-05-30	2003-05-30

Publications (1)

Publication Number	Publication Date
ZA200509521B true ZA200509521B (en)	2006-10-25

Family

ID=33563735

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200509521A ZA200509521B (en)	2003-05-30	2005-11-24	Modified fluorinated nucleoside analogues

Country Status (30)

Country	Link
US (8)	US7429572B2 (fr)
EP (8)	EP2345658A1 (fr)
JP (5)	JP4958158B2 (fr)
KR (1)	KR100883703B1 (fr)
CN (1)	CN100503628C (fr)
AR (6)	AR044566A1 (fr)
AU (1)	AU2004253860B2 (fr)
BR (3)	BRPI0410846B8 (fr)
CA (5)	CA2733842A1 (fr)
CO (1)	CO5660270A2 (fr)
CY (2)	CY1118020T1 (fr)
DK (1)	DK2604620T4 (fr)
ES (3)	ES2586668T3 (fr)
FI (1)	FI2604620T4 (fr)
HR (1)	HRP20160873T4 (fr)
HU (2)	HUE029877T2 (fr)
IL (2)	IL172259A (fr)
LT (2)	LT2604620T (fr)
MX (1)	MXPA05012788A (fr)
MY (1)	MY138477A (fr)
NO (5)	NO333700B1 (fr)
NZ (1)	NZ543867A (fr)
PL (3)	PL2604620T5 (fr)
PT (3)	PT3521297T (fr)
RU (1)	RU2358979C2 (fr)
SI (3)	SI2604620T2 (fr)
TR (1)	TR201906767T4 (fr)
TW (1)	TWI333956B (fr)
WO (1)	WO2005003147A2 (fr)
ZA (1)	ZA200509521B (fr)

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164523A (en) *	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
AP2006003708A0 (en)	2000-05-26	2006-08-31	Idenix Cayman Ltd	Methods and compositions for treating flavivirusesand pestiviruses
US8481712B2 (en)	2001-01-22	2013-07-09	Merck Sharp & Dohme Corp.	Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP2332952B1 (fr) *	2002-06-28	2015-04-29	IDENIX Pharmaceuticals, Inc.	Promédicaments à base de nucléosides modifiés en 2' et 3' pour le traitement d'infections par flavivirus
US7608600B2 (en) *	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) *	2002-06-28	2007-10-26	Idenix Cayman Ltd	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004002422A2 (fr) *	2002-06-28	2004-01-08	Idenix (Cayman) Limited	Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae
DK1576138T3 (en)	2002-11-15	2017-05-01	Idenix Pharmaceuticals Llc	2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
PL377287A1 (pl) *	2002-12-12	2006-01-23	Idenix (Cayman) Limited	Sposób wytwarzania 2'-rozgałęzionych nukleozydów
PT3521297T (pt) *	2003-05-30	2022-03-18	Gilead Pharmasset Llc	Análogos de nucleosídeo fluorados modificados
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
CN101023094B (zh) *	2004-07-21	2011-05-18	法莫赛特股份有限公司	烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1773856B1 (fr) *	2004-07-21	2012-02-01	Pharmasset, Inc.	Preparation de pyrimidines et purines 2-desoxy-2-fluoro-d-ribofuranosyl substitues en alkyle et leurs derives
KR101177590B1 (ko)	2004-09-14	2012-08-27	파마셋 인코포레이티드	2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조
US20080280842A1 (en) *	2004-10-21	2008-11-13	Merck & Co., Inc.	Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
JP2008523082A (ja)	2004-12-09	2008-07-03	リージェンツオブザユニバーシティオブミネソタ	抗菌活性および抗癌活性を有するヌクレオチド
MX2007010463A (es)	2005-02-28	2007-11-08	Genelabs Tech Inc	Profarmacos de nucleosido triciclico para tratar infecciones virales.
WO2006130217A2 (fr) *	2005-04-01	2006-12-07	The Regents Of The University Of California	Esters de phosphate de phosphonates de nucleosides substitues
WO2006116557A1 (fr) *	2005-04-25	2006-11-02	Genelabs Technologies, Inc.	Composes nucleosides pour le traitement d’infections virales
JP4705164B2 (ja)	2005-05-02	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
CN100478349C (zh) *	2005-06-20	2009-04-15	河南省凯特化学实业总公司	氟化核苷类化合物、其制备方法及其应用
US8278322B2 (en)	2005-08-01	2012-10-02	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
KR20080065272A (ko)	2005-09-26	2008-07-11	파마셋 인코포레이티드	항바이러스제로서의 변형된 4'-뉴클레오시드
KR101238461B1 (ko) *	2005-12-09	2013-03-05	길리어드 파마셋 엘엘씨	항바이러스성 뉴클레오시드
EP1976382B1 (fr) *	2005-12-23	2013-04-24	IDENIX Pharmaceuticals, Inc.	Procede pour la preparation d'un intermediaire synthetique pour la preparation de nucleosides ramifies
KR101237312B1 (ko)	2006-02-10	2013-03-04	삼진제약주식회사	피리미딘다이온 유도체를 포함하는 ｃ형 간염의 예방 및치료용 약학 조성물
JP2009526850A (ja)	2006-02-14	2009-07-23	メルクエンドカムパニーインコーポレーテッド	Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
US8895531B2 (en)	2006-03-23	2014-11-25	Rfs Pharma Llc	2′-fluoronucleoside phosphonates as antiviral agents
GB0609492D0 (en)	2006-05-15	2006-06-21	Angeletti P Ist Richerche Bio	Therapeutic agents
US8058260B2 (en) *	2006-05-22	2011-11-15	Xenoport, Inc.	2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
GB0612423D0 (en)	2006-06-23	2006-08-02	Angeletti P Ist Richerche Bio	Therapeutic agents
PL2084174T3 (pl) *	2006-10-10	2013-12-31	Gilead Pharmasset Llc	Sposób otrzymywania nukleozydów rybofuranozylopirymidynowych
US7968556B2 (en)	2006-10-19	2011-06-28	Signal Pharmaceuticals, Llc	Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US8138164B2 (en)	2006-10-24	2012-03-20	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
EP2076278B1 (fr)	2006-10-24	2015-05-06	Merck Sharp & Dohme Corp.	Inhibiteurs macrocycliques de la protéase HCV NS3
CN101583372A (zh)	2006-10-24	2009-11-18	默克公司	Hcv ns3蛋白酶抑制剂
KR101615500B1 (ko)	2006-10-27	2016-04-27	머크 샤프 앤드 돔 코포레이션	Ｈｃｖｎｓ3 프로테아제 억제제
AU2007318164B2 (en)	2006-10-27	2013-02-07	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
KR101118413B1 (ko) *	2006-12-18	2012-03-07	에프. 호프만-라 로슈 아게	3,5-다이-ｏ-아실-2-플루오로-2-ｃ-메틸-ｄ-리보노-감마-락톤의 제조 방법
GB0625345D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
AU2007335962B2 (en)	2006-12-20	2012-09-06	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Antiviral indoles
GB0625349D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
WO2008079206A1 (fr) *	2006-12-20	2008-07-03	Merck & Co., Inc.	Phosphoramidates cycliques nucléosidiques pour le traitement d'infections virales arn dépendantes
US20080261913A1 (en)	2006-12-28	2008-10-23	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2008085508A2 (fr) *	2007-01-05	2008-07-17	Merck & Co., Inc.	Phosphoramidates d'aryle nucléosidiques destinés au traitement de l'infection virale d'arn arn dépendante
WO2008090046A1 (fr) *	2007-01-23	2008-07-31	F. Hoffmann-La Roche Ag	Nouveau procédé servant à préparer de la 3,5-di-omicron-acyl-2-fluoro-2-c-méthyl-d-ribono-gamma-lactone
PL2144604T3 (pl) *	2007-02-28	2012-02-29	Conatus Pharmaceuticals Inc	Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
WO2008106167A1 (fr) *	2007-02-28	2008-09-04	Conatus Pharmaceuticals, Inc.	Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
AU2014233579B2 (en) *	2007-03-30	2016-06-23	Gilead Sciences, Inc.	Nucleoside phosphoramidate prodrugs
US7964580B2 (en) *	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) *	2007-05-22	2007-06-27	Angeletti P Ist Richerche Bio	Antiviral agents
CN100532388C (zh) *	2007-07-16	2009-08-26	郑州大学	2’-氟-4’-取代-核苷类似物、其制备方法及应用
CN101801982A (zh)	2007-07-17	2010-08-11	P.安杰莱蒂分子生物学研究所	用于治疗丙型肝炎感染的大环吲哚衍生物
CN101754974B (zh)	2007-07-19	2016-02-03	Msd意大利有限公司	作为抗病毒剂的大环化合物
GB0718575D0 (en)	2007-09-24	2007-10-31	Angeletti P Ist Richerche Bio	Nucleoside derivatives as inhibitors of viral polymerases
BRPI0821106A2 (pt) *	2007-11-29	2015-06-16	Ligand Pharm Inc	Pró-fármacos de nucleosídeo e usos dos mesmos
US8227431B2 (en)	2008-03-17	2012-07-24	Hetero Drugs Limited	Nucleoside derivatives
JP2011518882A (ja)	2008-04-28	2011-06-30	メルク・シャープ・エンド・ドーム・コーポレイション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
US8173621B2 (en) *	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
RU2519947C2 (ru) *	2008-07-02	2014-06-20	Айденикс Фармасьютикалз, Инк.	Соединения и фармацевтические композиции для лечения вирусных инфекций
PT2310095E (pt)	2008-07-22	2012-11-16	Angeletti P Ist Richerche Bio	Compostos de quinoxalina macrocílicos como inibidores da protease ns3 do hcv
NZ593649A (en)	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Nucleoside analogs
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
EP2376088B1 (fr) *	2008-12-23	2017-02-22	Gilead Pharmasset LLC	Phosphoramidates de nucléosides de type 2-amino-purine 6-O-substituée
CA2748792A1 (fr) *	2009-01-07	2010-07-15	Samuel Earl Hopkins	Combinaison d'un derive de cyclosporine et de nucleosides pour traiter le virus de l'hepatite c (vhc)
WO2010082050A1 (fr)	2009-01-16	2010-07-22	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Composés benzoxazocines substitués 7-aminoalkyle macrocycycliques destinés au traitement des infections par hépatite c
AR075584A1 (es) *	2009-02-27	2011-04-20	Intermune Inc	COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101967A2 (fr)	2009-03-04	2010-09-10	Idenix Pharmaceuticals, Inc.	Inhibiteurs de phosphothiophène et phosphothiazole vhc polymérase
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
TW201107342A (en) *	2009-05-20	2011-03-01	Chimerix Inc	Compounds, compositions and methods for treating viral infection
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
EP2459582B1 (fr)	2009-07-30	2015-05-27	Merck Sharp & Dohme Corp.	Inhibiteurs de protéase ns3 du virus de l'hépatite c
US20110027229A1 (en)	2009-07-31	2011-02-03	Medtronic, Inc.	Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
WO2011017389A1 (fr)	2009-08-05	2011-02-10	Idenix Pharmaceuticals, Inc.	Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de lhépatite c
RU2557242C2 (ru)	2009-10-26	2015-07-20	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Способы получения и очистки гетероарильных соединений
WO2011063076A1 (fr)	2009-11-19	2011-05-26	Itherx Pharmaceuticals, Inc.	Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
AR079528A1 (es)	2009-12-18	2012-02-01	Idenix Pharmaceuticals Inc	Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
CA2784646A1 (fr)	2009-12-18	2011-06-23	Boehringer Ingelheim International Gmbh	Polytherapie du vhc
JP2013527145A (ja)	2010-03-31	2013-06-27	ギリード・ファーマセット・エルエルシー	リン含有活性化剤の立体選択的合成
UY33310A (es)	2010-03-31	2011-10-31	Pharmasset Inc	Sintesis estereoselectiva de activos que contienen fosforo
PL3290428T3 (pl)	2010-03-31	2022-02-07	Gilead Pharmasset Llc	Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
BR112012024661A2 (pt)	2010-04-01	2015-09-15	Centre Nat Rech Scient	composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
MX2013003179A (es) *	2010-09-20	2013-04-24	Gilead Sciences Inc	Analogos de carba-nucleosidos sustituidos con 2 '-fluoro para tratamiento antiviral.
WO2012062691A1 (fr)	2010-11-09	2012-05-18	F. Hoffmann-La Roche Ag	Compositions pharmaceutiques pour le traitement des infections par le virus de l'hépatite c
ES2716158T3 (es)	2010-11-30	2019-06-10	Gilead Pharmasset Llc	2'-spiro-nucleótidos para el tratamiento de hepatitis C
WO2012080050A1 (fr)	2010-12-14	2012-06-21	F. Hoffmann-La Roche Ag	Formes solides d'un composé de phénoxybenzènesulfonyle
TW201701876A (zh) *	2010-12-20	2017-01-16	吉李德科學股份有限公司	治療ｃ型肝炎病毒（ｈｃｖ）之方法
US9353100B2 (en)	2011-02-10	2016-05-31	Idenix Pharmaceuticals Llc	Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US20120252721A1 (en)	2011-03-31	2012-10-04	Idenix Pharmaceuticals, Inc.	Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2691409B1 (fr)	2011-03-31	2018-02-21	Idenix Pharmaceuticals LLC.	Composés et compositions pharmaceutiques pour le traitement d'infections virales
WO2012142093A2 (fr)	2011-04-13	2012-10-18	Merck Sharp & Dohme Corp.	Dérivés nucléosides à substitution 2'-cyano et leurs procédés d'utilisation pour traitement de maladies virales
WO2012142075A1 (fr)	2011-04-13	2012-10-18	Merck Sharp & Dohme Corp.	Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales
BR112013026345A2 (pt) *	2011-04-13	2019-04-24	Merck Sharp & Dohe Corp.	composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
CN103476783A (zh)	2011-04-13	2013-12-25	吉里德科学公司	用于抗病毒治疗的1’-取代的嘧啶n-核苷类似物
US20130018011A1 (en) *	2011-06-10	2013-01-17	Hassan Javanbakht	Method of treating dengue fever
EP2731433A4 (fr)	2011-07-13	2014-12-31	Merck Sharp & Dohme	Analogues de nucléosides 5'-substitués et leurs procédés d'utilisation pour le traitement de maladies virales
EP2731434A4 (fr)	2011-07-13	2014-12-31	Merck Sharp & Dohme	Dérivés de nucléosides 5'-substitués et leurs procédés d'utilisation pour le traitement de maladies virales
JP2014526474A (ja)	2011-09-12	2014-10-06	アイディニックスファーマシューティカルズインコーポレイテッド	ウイルス感染の治療のための化合物および薬学的組成物
WO2013039920A1 (fr)	2011-09-12	2013-03-21	Idenix Pharmaceuticals, Inc.	Composés de carbonyloxyméthylphosphoramidate substitué et compositions pharmaceutiques servant à traiter les infections virales
MX354958B (es) *	2011-09-16	2018-03-27	Gilead Pharmasset Llc	Metodos para el tratamiento de vhc.
EP2768838A1 (fr)	2011-10-14	2014-08-27	IDENIX Pharmaceuticals, Inc.	Phosphates 3',5'-cycliques substitués de composés nucléotidiques purines et compositions pharmaceutiques pour le traitement d'infections virales
CN103998036B (zh)	2011-10-19	2017-05-31	西格诺药品有限公司	利用tor激酶抑制剂治疗癌症
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
BR112014005617A2 (pt)	2011-10-21	2017-06-13	Abbvie Inc	tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
SE1450019A1 (sv)	2011-10-21	2014-01-10	Abbvie Inc	Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US9328138B2 (en)	2011-11-15	2016-05-03	Msd Italia S.R.L.	HCV NS3 protease inhibitors
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
WO2013082476A1 (fr)	2011-11-30	2013-06-06	Emory University	Inhibiteurs de jak antiviraux utiles dans le traitement ou la prévention d'infections rétrovirales et autres infections virales
WO2013082344A1 (fr)	2011-12-02	2013-06-06	Signal Pharmaceuticals, Llc	Compositions pharmaceutiques de 7-(6-(2-hydroxypropan-2-y1)pyridin-3-yl)-1-((trans)-4-méthoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, forme solide de celles-ci et leurs procédés d'utilisation
WO2013090420A2 (fr) *	2011-12-12	2013-06-20	Catabasis Pharmaceuticals, Inc.	Conjugués acide gras antivirus et leurs utilisations
US20130217644A1 (en)	2012-02-13	2013-08-22	Idenix Pharmaceuticals, Inc.	Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
EA201491525A1 (ru)	2012-02-14	2014-12-30	Юниверсити Оф Джорджиа Рисерч Фаундэйшн, Инк.	Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae
EP2817029B1 (fr)	2012-02-24	2019-07-10	Signal Pharmaceuticals, LLC	Procédés de traitement du cancer du poumon non à petites cellules à l'aide d'une thérapie combinée d'inhibiteur de kinase
AU2013266393B2 (en)	2012-05-22	2017-09-28	Idenix Pharmaceuticals Llc	D-amino acid compounds for liver disease
WO2013177188A1 (fr)	2012-05-22	2013-11-28	Idenix Pharmaceuticals, Inc.	Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
US9296778B2 (en)	2012-05-22	2016-03-29	Idenix Pharmaceuticals, Inc.	3′,5′-cyclic phosphate prodrugs for HCV infection
KR20150014457A (ko)	2012-05-25	2015-02-06	얀센 알 앤드 디 아일랜드	우라실 스피로옥세탄 뉴클레오시드
WO2013188396A1 (fr) *	2012-06-12	2013-12-19	F. Hoffmann-La Roche Ag	Combinaison d'agents thérapeutiques pour le traitement d'une infection par le vhc
WO2014047117A1 (fr)	2012-09-18	2014-03-27	Bristol-Myers Squibb Company	Procédé de préparation de dérivés phosphoramidatés de composés nucléosidiques utilisables en vue du traitement d'infections virales
WO2014052638A1 (fr)	2012-09-27	2014-04-03	Idenix Pharmaceuticals, Inc.	Esters et malonates de promédicaments à base de s-acyl-2-thioéthyle (sate)
MX353422B (es)	2012-10-08	2018-01-12	Idenix Pharmaceuticals Llc	Análogos de 2'-cloronucleósido para infección por vhc.
WO2014059902A1 (fr)	2012-10-17	2014-04-24	Merck Sharp & Dohme Corp.	Dérivés nucléosides substitués 2'-disubstitués et leurs procédés d'utilisation pour le traitement de maladies virales
WO2014059901A1 (fr)	2012-10-17	2014-04-24	Merck Sharp & Dohme Corp.	Dérivés nucléosides à substitution 2'-cyano et leurs méthodes d'utilisation pour le traitement de maladies virales
AR092959A1 (es) *	2012-10-17	2015-05-06	Merck Sharp & Dohme	Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2909223B1 (fr)	2012-10-19	2017-03-22	Idenix Pharmaceuticals LLC	Composés dinucléotides contre une infection par le vhc
EP2909222B1 (fr)	2012-10-22	2021-05-26	Idenix Pharmaceuticals LLC	Nucléosides 2', 4'-pontés pour l'infection par le vhc
CN103804417B (zh) *	2012-11-13	2017-09-19	北京美倍他药物研究有限公司	抗乙肝病毒药物
US20140140952A1 (en)	2012-11-14	2014-05-22	Idenix Pharmaceuticals, Inc.	D-Alanine Ester of Sp-Nucleoside Analog
WO2014078427A1 (fr)	2012-11-14	2014-05-22	Idenix Pharmaceuticals, Inc.	Ester de d-alanine d'analogue de rp-nucléoside
AU2013344757A1 (en)	2012-11-19	2015-05-21	Merck Sharp & Dohme Corp.	2 -alkynyl substituted nucleoside derivatives for treating viral diseases
EP2935304A1 (fr) *	2012-12-19	2015-10-28	IDENIX Pharmaceuticals, Inc.	4'-fluoro-nucléosides pour le traitement du vhc
BR112015014457A2 (pt)	2012-12-21	2017-11-21	Alios Biopharma Inc	composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
EA201591327A1 (ru)	2013-01-16	2015-12-30	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
SG10201706949VA (en)	2013-01-31	2017-09-28	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
US10034893B2 (en)	2013-02-01	2018-07-31	Enanta Pharmaceuticals, Inc.	5, 6-D2 uridine nucleoside/tide derivatives
WO2014121417A1 (fr)	2013-02-07	2014-08-14	Merck Sharp & Dohme Corp.	Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2014121418A1 (fr)	2013-02-07	2014-08-14	Merck Sharp & Dohme Corp.	Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c
WO2014121416A1 (fr)	2013-02-07	2014-08-14	Merck Sharp & Dohme Corp.	Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
EP2970358B1 (fr)	2013-03-04	2021-06-30	Idenix Pharmaceuticals LLC	3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
WO2014137930A1 (fr)	2013-03-04	2014-09-12	Idenix Pharmaceuticals, Inc.	Nucléosides de thiophosphate pour le traitement du vhc
US20140271547A1 (en)	2013-03-13	2014-09-18	Idenix Pharmaceuticals, Inc.	Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
JP2016519055A (ja) *	2013-03-14	2016-06-30	カイメロケムエルエルシー	アミノ酸側鎖を含有する合成重合体
WO2014165542A1 (fr)	2013-04-01	2014-10-09	Idenix Pharmaceuticals, Inc.	2',4'-fluoronucléosides pour le traitement du vhc
EP2984097B1 (fr)	2013-04-12	2017-03-29	Achillion Pharmaceuticals, Inc.	Dérivé de nucléoside d'activité élevée pour le traitement du vhc
US9358232B2 (en)	2013-04-17	2016-06-07	Signal Pharmaceuticals, Llc	Methods for treating cancer using TOR kinase inhibitor combination therapy
SG10201708111YA (en)	2013-04-17	2017-11-29	Signal Pharm Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6382948B2 (ja)	2013-04-17	2018-08-29	シグナルファーマシューティカルズ，エルエルシー	癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
BR112015026300A2 (pt)	2013-04-17	2017-07-25	Signal Pharm Llc	formulações farmacêuticas, processos, formas sólidas e métodos de uso relativos a 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridina-3-il)-3,4-dihidropirazina[2,3-b] pirazina-2(1h)-ona
CN105377260B (zh)	2013-04-17	2020-06-12	西格诺药品有限公司	二氢吡嗪并-吡嗪类化合物在制备治疗癌症的药物中的应用
CA2908353C (fr)	2013-04-17	2021-11-02	Signal Pharmaceuticals, Llc	Traitement du cancer par des dihydropyrazino-pyrazines
EP2986322A1 (fr)	2013-04-17	2016-02-24	Signal Pharmaceuticals, LLC	Polythérapie comprenant un inhibiteur de kinase tor et un composé de quinazolinone substitué en 5 pour le traitement du cancer
US20180200280A1 (en)	2013-05-16	2018-07-19	Riboscience Llc	4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
CN105307662B (zh) *	2013-05-16	2019-06-04	里博科学有限责任公司	4’-氟-2’-甲基取代的核苷衍生物
CA2912627C (fr)	2013-05-29	2022-03-15	Signal Pharmaceuticals, Llc	Compositions pharmaceutiques de 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-l-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(lh)-one, forme solide de celle-ci et p rocedes pour les utiliser
US10005779B2 (en)	2013-06-05	2018-06-26	Idenix Pharmaceuticals Llc	1′,4′-thio nucleosides for the treatment of HCV
WO2014204831A1 (fr)	2013-06-18	2014-12-24	Merck Sharp & Dohme Corp.	Dérivés de nucléosides cycliques à substitution phosphonate et leurs méthodes d'utilisation pour le traitement de maladies virales
US20150037282A1 (en)	2013-08-01	2015-02-05	Idenix Pharmaceuticals, Inc.	D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015030853A1 (fr)	2013-08-27	2015-03-05	Gilead Pharmasset Llc	Préparation combinée de deux composés antiviraux
WO2015042375A1 (fr)	2013-09-20	2015-03-26	Idenix Pharmaceuticals, Inc.	Inhibiteurs du virus de l'hépatite c
MX2016004558A (es)	2013-10-11	2016-07-06	Alios Biopharma Inc	Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
WO2015061683A1 (fr)	2013-10-25	2015-04-30	Idenix Pharmaceuticals, Inc.	Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
WO2015066370A1 (fr)	2013-11-01	2015-05-07	Idenix Pharmaceuticals, Inc.	Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc
EP3074399A1 (fr)	2013-11-27	2016-10-05	Idenix Pharmaceuticals LLC	Analogues de nucléoside 2'-dichloro et 2'-fluoro-2'-chloro analogues pour l'infection par le vhc
WO2015095419A1 (fr)	2013-12-18	2015-06-25	Idenix Pharmaceuticals, Inc.	Nucléosides 4'-or pour le traitement du vhc
CN106061984A (zh)	2014-02-13	2016-10-26	配体药物公司	前药化合物及其用途
US20170066779A1 (en)	2014-03-05	2017-03-09	Idenix Pharmaceuticals Llc	Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (fr)	2014-03-05	2015-09-11	Idenix Pharmaceuticals, Inc.	Compositions pharmaceutiques comprenant un inhibiteur de flaviviridae hétéroarylène fusionné en 5,5 et son utilisation pour le traitement ou la prévention d'une infection par les flaviviridae
CN104926902A (zh) *	2014-03-17	2015-09-23	张容霞	2`-取代-2,2`-脱水尿苷或2`-取代-2,2`-脱水胞苷化合物及其制备方法和用途
WO2015160882A1 (fr)	2014-04-16	2015-10-22	Signal Pharmaceuticals, Llc	Formes solides comprenant de la 7-(6- (2-hydroxypropan-2-yl) pyridin-3-yl)-1-(trans)-4-méthoxycyclohexyl)-3, 4-dihydropyrazino[2,3-b] pyrazin-2(1h)-one, et un co-formeur, leurs compositions et leurs procédés d'utilisation
WO2015160868A1 (fr)	2014-04-16	2015-10-22	Signal Pharmaceuticals, Llc	Méthodes de traitement du cancer à l'aide d'une polythérapie avec des inhibiteurs de la kinase tor
US9512129B2 (en)	2014-04-16	2016-12-06	Signal Pharmaceuticals, Llc	Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
WO2015161137A1 (fr)	2014-04-16	2015-10-22	Idenix Pharmaceuticals, Inc.	Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
CN107113222B (zh)	2014-06-06	2020-09-01	谷歌有限责任公司	基于环境的主动聊天信息系统
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
NZ629796A (en)	2014-07-14	2015-12-24	Signal Pharm Llc	Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
KR20170024120A (ko)	2014-07-14	2017-03-06	시그날 파마소티칼 엘엘씨	치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
US10526363B2 (en)	2014-08-15	2020-01-07	Merck Sharp & Dohme Corp.	Substituted phosphoramidate compounds and uses thereof
WO2016033164A1 (fr)	2014-08-26	2016-03-03	Enanta Pharmaceuticals, Inc.	Dérivés de nucléosides et de nucléotides
CN104327138B (zh) *	2014-10-21	2017-05-10	齐鲁制药有限公司	Psi‑7977中间体化合物的制备方法
CN107074899A (zh) *	2014-10-31	2017-08-18	桑多斯股份公司	改进的氟化工艺
WO2016073756A1 (fr)	2014-11-06	2016-05-12	Enanta Pharmaceuticals, Inc.	Dérivés de nucléosides/nucléotides deutérés
US9732110B2 (en)	2014-12-05	2017-08-15	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
GEP20237502B (en)	2015-03-06	2023-04-25	Atea Pharmaceuticals Inc	B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
US10618926B2 (en)	2015-04-02	2020-04-14	Merck Sharp & Dohme	Process for making phosphoramidate protected nucleoside compounds
WO2016182935A1 (fr) *	2015-05-08	2016-11-17	Abbvie Inc.	Composés anti-viraux
WO2016182937A1 (fr) *	2015-05-08	2016-11-17	Abbvie Inc.	Composés anti-viraux
WO2016182939A1 (fr) *	2015-05-08	2016-11-17	Abbvie Inc.	Composés anti-viraux
WO2016182936A1 (fr) *	2015-05-08	2016-11-17	Abbvie Inc.	Composés anti-viraux
WO2016182934A1 (fr) *	2015-05-08	2016-11-17	Abbvie Inc.	Composés anti-viraux
MX2018002707A (es)	2015-09-02	2018-08-01	Abbvie Inc	Derivados de tetrahidrofurano antivirales.
US11192914B2 (en)	2016-04-28	2021-12-07	Emory University	Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (fr)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Dégronimères hétérocycliques pour la dégradation de protéines cibles
CN109562113A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的螺环降解决定子体
BR112018073858A2 (pt)	2016-05-27	2019-02-26	Gilead Sciences, Inc.	métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3
US10202412B2 (en)	2016-07-08	2019-02-12	Atea Pharmaceuticals, Inc.	β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (fr)	2016-07-14	2018-01-18	Atea Pharmaceuticals, Inc.	Nucléotides de purine beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substitué-4'-fluoro-n6-substitué-6-amino-2-substitué pour le traitement de l'infection par le virus de l'hépatite c
AU2017324939B2 (en)	2016-09-07	2021-10-14	Atea Pharmaceuticals, Inc.	2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
EP3577124A4 (fr) *	2017-02-01	2021-01-06	ATEA Pharmaceuticals, Inc.	Sel d'hémi-sulfate nucléotidique pour le traitement du virus de l'hépatite c
US11096940B2 (en)	2017-06-22	2021-08-24	Celgene Corporation	Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
IL273398B1 (en)	2017-09-21	2024-10-01	Riboscience Llc	History of 4'-Fluoro-2'-Methyl Modified Nucleoside as HCV RNA Replication Inhibitors
EP3737676B1 (fr)	2018-01-09	2024-03-06	Ligand Pharmaceuticals, Inc.	Composés acétal et leurs utilisations thérapeutiques
JP2021521118A (ja)	2018-04-10	2021-08-26	アテアファーマシューティカルズ，インコーポレイテッド	肝硬変を伴うｈｃｖ感染患者の治療
WO2020007070A1 (fr) *	2018-07-02	2020-01-09	河南真实生物科技有限公司	Forme cristalline, procédé de préparation, et utilisation d'un nucléoside substitué en position 4'
WO2020072931A2 (fr) *	2018-10-04	2020-04-09	Octagon Therapeutics Inc.	Inhibiteurs nucléosidiques d'impdh pré-activés en tant que médicaments anti-infectieux
KR101970963B1 (ko)	2018-12-19	2019-04-23	주식회사 엠디헬스케어	황열 바이러스 ediii에 특이적으로 결합하는 dna 압타머 및 이의 용도
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
CN111363712B (zh) *	2020-03-23	2020-11-03	华东师范大学	一种表达微管β亚基与蛋白A的D结构域融合蛋白的基因工程菌株及其构建方法
JP2023540562A (ja) *	2020-09-04	2023-09-25	ヴァーヴ・セラピューティクス，インコーポレーテッド	Ｒｎａをキャッピングするための組成物および方法

Family Cites Families (254)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US29835A (en)		1860-08-28		Surveyor s instrument
CA1316A (en)		1872-01-20	J.P. Cleveland	Improvements in boilers for heating sap and other liquids
CA100197A (fr)	1906-05-01	1906-07-24	Cecil Beckwith	Appareil pour placer les pneus pneumatiques sur les roues
US3480613A (en)	1967-07-03	1969-11-25	Merck & Co Inc	2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
US3798209A (en)	1971-06-01	1974-03-19	Icn Pharmaceuticals	1,2,4-triazole nucleosides
USRE29835E (en)	1971-06-01	1978-11-14	Icn Pharmaceuticals	1,2,4-Triazole nucleosides
US4526988A (en) *	1983-03-10	1985-07-02	Eli Lilly And Company	Difluoro antivirals and intermediate therefor
FR2562543B1 (fr)	1984-04-10	1987-09-25	Elf Aquitaine	Nouveaux phosphonites cycliques, leur preparation et applications
NL8403224A (nl) *	1984-10-24	1986-05-16	Oce Andeno Bv	Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US5223263A (en)	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
EP0285884A3 (fr)	1987-03-20	1990-07-04	Bristol-Myers Squibb Company	Procédé pour la préparation de nucléosides 2',3'-didéoxy
GB8719367D0 (en)	1987-08-15	1987-09-23	Wellcome Found	Therapeutic compounds
JPH03501253A (ja)	1987-09-22	1991-03-22	ザリージェンツオブザユニバーシティオブカリフォルニア	エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
DE3825158C1 (fr)	1988-07-07	1989-06-01	Franz Bisping Gmbh & Co, 4400 Muenster, De
SE8802687D0 (sv)	1988-07-20	1988-07-20	Astra Ab	Nucleoside derivatives
US5616702A (en)	1988-11-15	1997-04-01	Merrell Pharmaceuticals Inc.	2-'-ethenylidene cytidine, uridine and guanosine derivatives
US5705363A (en)	1989-03-02	1998-01-06	The Women's Research Institute	Recombinant production of human interferon τ polypeptides and nucleic acids
US5075225A (en)	1989-04-06	1991-12-24	The Texas A&M University System	Process for the enzymatic synthesis of nucleosides
US5411947A (en) *	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en)	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
DE3924424A1 (de)	1989-07-24	1991-01-31	Boehringer Mannheim Gmbh	Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
US5463092A (en)	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5026687A (en)	1990-01-03	1991-06-25	The United States Of America As Represented By The Department Of Health And Human Services	Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
DE69132332T2 (de)	1990-04-06	2000-11-30	Genelabs Technologies, Inc.	Hepatitis c-virus-epitope
AU7872491A (en)	1990-05-07	1991-11-27	Vical, Inc.	Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
AU7623991A (en)	1990-05-17	1991-11-21	Syntex (U.S.A.) Inc.	Antiviral agents
JPH05507279A (ja)	1990-05-29	1993-10-21	ネクススター・ファーマシューティカルズ・インコーポレイテッド	グリセロールジ―およびトリホスフェート誘導体の合成
EP0533833B1 (fr)	1990-06-13	1995-12-20	GLAZIER, Arnold	Promedicaments phosphoreux
US5272152A (en)	1990-07-02	1993-12-21	E. R. Squibb & Sons, Inc.	Purinyl and pyrimidinyl tetrahydrofurans
US5372808A (en)	1990-10-17	1994-12-13	Amgen Inc.	Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5149794A (en)	1990-11-01	1992-09-22	State Of Oregon	Covalent lipid-drug conjugates for drug targeting
US5543390A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US5256641A (en)	1990-11-01	1993-10-26	State Of Oregon	Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization	Covalent polar lipid-peptide conjugates for use in salves
US5595732A (en)	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
US5157027A (en)	1991-05-13	1992-10-20	E. R. Squibb & Sons, Inc.	Bisphosphonate squalene synthetase inhibitors and method
EP0594677A4 (en)	1991-07-12	1997-09-17	Vical Inc	Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en)	1991-07-23	1996-09-10	Nexstar Pharmaceuticals, Inc.	Lipid conjugates of therapeutic peptides and protease inhibitors
TW224053B (fr)	1991-09-13	1994-05-21	Paul B Chretien
US5676942A (en)	1992-02-10	1997-10-14	Interferon Sciences, Inc.	Composition containing human alpha interferon species proteins and method for use thereof
US5405598A (en)	1992-02-24	1995-04-11	Schinazi; Raymond F.	Sensitizing agents for use in boron neutron capture therapy
US5610054A (en)	1992-05-14	1997-03-11	Ribozyme Pharmaceuticals, Inc.	Enzymatic RNA molecule targeted against Hepatitis C virus
HU214980B (hu) *	1992-09-01	1998-08-28	Eli Lilly And Co.	Eljárás nukleozidok anomerizálására
GB9226729D0 (en)	1992-12-22	1993-02-17	Wellcome Found	Therapeutic combination
US5496546A (en)	1993-02-24	1996-03-05	Jui H. Wang	Compositions and methods of application of reactive antiviral polyadenylic acid derivatives
WO1994026273A1 (fr)	1993-05-12	1994-11-24	Hostetler Karl Y	Derives d'acyclovir a usage topique
TW374087B (en)	1993-05-25	1999-11-11	Univ Yale	L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
AU688344B2 (en)	1993-07-19	1998-03-12	Mitsubishi-Tokyo Pharmaceuticals, Inc.	Hepatitis C virus proliferation inhibitor
US7375198B2 (en) *	1993-10-26	2008-05-20	Affymetrix, Inc.	Modified nucleic acid probes
US6156501A (en)	1993-10-26	2000-12-05	Affymetrix, Inc.	Arrays of modified nucleic acid probes and methods of use
AU691225B2 (en)	1993-11-10	1998-05-14	Schering Corporation	Improved interferon polymer conjugates
US5951974A (en)	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
US5587362A (en)	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
AU6550394A (en)	1994-03-11	1995-09-25	Isis Pharmaceuticals, Inc.	Novel pyrimidine nucleosides
DE4415539C2 (de)	1994-05-03	1996-08-01	Osama Dr Dr Med Omer	Pflanzen mit virustatischer und antiviraler Wirkung
JPH10501809A (ja) *	1994-06-22	1998-02-17	ネクスターファーマスーティカルズ，インコーポレイテッド	分子内求核置換による公知および新規２′−ヌクレオシドの新規製造方法
DE4432623A1 (de)	1994-09-14	1996-03-21	Huels Chemische Werke Ag	Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5559101A (en)	1994-10-24	1996-09-24	Genencor International, Inc.	L-ribofuranosyl nucleosides
US5738846A (en)	1994-11-10	1998-04-14	Enzon, Inc.	Interferon polymer conjugates and process for preparing the same
US5696277A (en)	1994-11-15	1997-12-09	Karl Y. Hostetler	Antiviral prodrugs
US6391859B1 (en) *	1995-01-27	2002-05-21	Emory University	[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) *	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
GB9505025D0 (en)	1995-03-13	1995-05-03	Medical Res Council	Chemical compounds
JP3786447B2 (ja)	1995-03-31	2006-06-14	エーザイ株式会社	Ｃ型肝炎の予防・治療剤
DE19514523A1 (de)	1995-04-12	1996-10-17	Schering Ag	Neue Cytosin- und Cytidinderivate
ATE318896T1 (de)	1995-09-27	2006-03-15	Univ Emory	Rekombinante rna-replikase von hepatitis-c-virus
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
EP0882058A1 (fr)	1995-11-02	1998-12-09	Chong Kun Dang Corp	Nouveaux derives de nucleosides et procede de preparation correspondant
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
GB9602028D0 (en) *	1996-02-01	1996-04-03	Amersham Int Plc	Nucleoside analogues
US5980884A (en)	1996-02-05	1999-11-09	Amgen, Inc.	Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
JP2000506010A (ja) *	1996-02-29	2000-05-23	イミューソルインコーポレイテッド	Ｃ型肝炎ウイルスリボザイム
US5633388A (en) *	1996-03-29	1997-05-27	Viropharma Incorporated	Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en)	1996-03-29	1998-11-03	Viropharma Incorporated	Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en)	1996-05-10	1999-11-23	Schering Corporation	Synthetic inhibitors of hepatitis C virus NS3 protease
GB9609932D0 (en)	1996-05-13	1996-07-17	Hoffmann La Roche	Use of IL-12 and IFN alpha for the treatment of infectious diseases
US5891874A (en)	1996-06-05	1999-04-06	Eli Lilly And Company	Anti-viral compound
US5837257A (en)	1996-07-09	1998-11-17	Sage R&D	Use of plant extracts for treatment of HIV, HCV and HBV infections
US6049333A (en) *	1996-09-03	2000-04-11	Time Warner Entertainment Company, L.P.	System and method for providing an event database in a telecasting system
JP3927630B2 (ja)	1996-09-27	2007-06-13	エーザイ・アール・アンド・ディー・マネジメント株式会社	ウイルス感染症の予防・治療剤
US5922757A (en)	1996-09-30	1999-07-13	The Regents Of The University Of California	Treatment and prevention of hepatic disorders
WO1998015563A1 (fr)	1996-10-09	1998-04-16	Pharmasset, Ltd.	Trisanhydrides bicycliques de tetraphosphonate
BR9714349A (pt) *	1996-10-16	2000-11-14	Icn Pharmaceuticals	L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
US6509320B1 (en) *	1996-10-16	2003-01-21	Icn Pharmaceuticals, Inc.	Purine L-nucleosides, analogs and uses thereof
US6455690B1 (en)	1996-10-16	2002-09-24	Robert Tam	L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
CZ120699A3 (cs)	1996-10-16	1999-09-15	Icn Pharmaceuticals, Inc.	Monocyklická L-nukleosidová analoga a jejich využití
EP2314598A1 (fr)	1996-10-18	2011-04-27	Vertex Pharmaceuticals Incorporated	Inhibiteurs de la protéase NS3 du virus de l'hépatite C
GB9623908D0 (en)	1996-11-18	1997-01-08	Hoffmann La Roche	Amino acid derivatives
IL119833A (en)	1996-12-15	2001-01-11	Lavie David	Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US20020127371A1 (en) *	2001-03-06	2002-09-12	Weder Donald E.	Decorative elements provided with a circular or crimped configuration at point of sale or point of use
US6004933A (en)	1997-04-25	1999-12-21	Cortech Inc.	Cysteine protease inhibitors
PL193237B1 (pl)	1997-06-30	2007-01-31	Merz Pharma Gmbh & Co Kgaa	Pochodne 1-aminoalkilocykloheksanu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
JP4452401B2 (ja)	1997-08-11	2010-04-21	ベーリンガーインゲルハイム（カナダ）リミテッド	Ｃ型肝炎ウイルス阻害ペプチドアナログ
DE69801970T2 (de)	1997-09-21	2002-06-13	Schering Corp., Kenilworth	Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infektion
US6703374B1 (en) *	1997-10-30	2004-03-09	The United States Of America As Represented By The Department Of Health And Human Services	Nucleosides for imaging and treatment applications
AU758426B2 (en)	1997-10-30	2003-03-20	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Nucleosides for imaging and treatment applications
US5981709A (en)	1997-12-19	1999-11-09	Enzon, Inc.	α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
KR100954390B1 (ko)	1998-02-25	2010-04-26	에모리 유니버시티	2'-플루오로뉴클레오사이드
US6787305B1 (en)	1998-03-13	2004-09-07	Invitrogen Corporation	Compositions and methods for enhanced synthesis of nucleic acid molecules
GB9806815D0 (en)	1998-03-30	1998-05-27	Hoffmann La Roche	Amino acid derivatives
TWI277424B (en)	1998-05-15	2007-04-01	Schering Corp	Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
ATE307597T1 (de)	1998-06-08	2005-11-15	Hoffmann La Roche	Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
PT2415776T (pt)	1998-08-10	2016-07-07	Novartis Ag	Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
CN1245808A (zh)	1998-08-21	2000-03-01	同济医科大学附属同济医院	抗肝炎病毒化合物及其制备方法和在制药中的应用
FR2784892B1 (fr)	1998-10-23	2001-04-06	Smith & Nephew Kinetec Sa	Attelle de mobilisation passive repliable pour membre inferieur
EP1140143A2 (fr)	1998-12-18	2001-10-10	Schering Corporation	Traitement du vhc par induction d'interferon-alpha pegyle combine la ribavirine
WO2001032153A2 (fr)	1999-11-04	2001-05-10	Shire Biochem Inc.	Procede de traitement ou de prevention de l'infection virale par flaviviridae faisant appel a des analogues des nucleosides
CA2391279A1 (fr) *	1999-11-12	2001-05-17	Pharmasset Limited	Synthese de 2'-deoxy-l-nucleosides
US6495677B1 (en)	2000-02-15	2002-12-17	Kanda S. Ramasamy	Nucleoside compounds
WO2001060315A2 (fr)	2000-02-18	2001-08-23	Shire Biochem Inc.	Methode de traitement ou de prevention d'infections a flavivirus a l'aide d'analogues nucleosidiques
BR0110023A (pt)	2000-04-13	2003-12-30	Pharmasset Ltd	Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite
WO2001081359A1 (fr)	2000-04-20	2001-11-01	Schering Corporation	Traitement combine de ribavirine-interferon alfa pour eliminer l'arn-vhc decelable chez un patient souffrant d'infections chroniques par l'hepatite c
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
EA005890B1 (ru)	2000-05-26	2005-06-30	Айденикс (Кайман) Лимитед	СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
AP2006003708A0 (en)	2000-05-26	2006-08-31	Idenix Cayman Ltd	Methods and compositions for treating flavivirusesand pestiviruses
US6787526B1 (en)	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
FR2810322B1 (fr) *	2000-06-14	2006-11-10	Pasteur Institut	PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP)
MY141594A (en)	2000-06-15	2010-05-14	Novirio Pharmaceuticals Ltd	3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6815542B2 (en)	2000-06-16	2004-11-09	Ribapharm, Inc.	Nucleoside compounds and uses thereof
UA72612C2 (en) *	2000-07-06	2005-03-15		Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
JP2004504407A (ja)	2000-07-21	2004-02-12	コルバス・インターナショナル・インコーポレイテッド	Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
AR034127A1 (es)	2000-07-21	2004-02-04	Schering Corp	Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AR029851A1 (es)	2000-07-21	2003-07-16	Dendreon Corp	Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
MXPA03000626A (es)	2000-07-21	2004-07-30	Schering Corp	Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
US7018985B1 (en) *	2000-08-21	2006-03-28	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
US6897201B2 (en) *	2000-08-21	2005-05-24	Inspire Pharmaceuticals, Inc.	Compositions and methods for the treatment of glaucoma or ocular hypertension
AR039558A1 (es) *	2000-08-21	2005-02-23	Inspire Pharmaceuticals Inc	Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US20030008841A1 (en)	2000-08-30	2003-01-09	Rene Devos	Anti-HCV nucleoside derivatives
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20030087873A1 (en)	2000-10-18	2003-05-08	Lieven Stuyver	Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
NZ575481A (en)	2000-10-18	2010-10-29	Pharmasset Inc	Simultaneous quantification of nucleic acids in diseased cells
EP1326594A2 (fr)	2000-10-18	2003-07-16	Schering Corporation	Polytherapie a base de ribavirine et d'interferon alpha pegyle contre le virus de l'hepatite c
US6555677B2 (en) *	2000-10-31	2003-04-29	Merck & Co., Inc.	Phase transfer catalyzed glycosidation of an indolocarbazole
CN100391967C (zh)	2000-11-20	2008-06-04	布里斯托尔-迈尔斯斯奎布公司	丙型肝炎三肽抑制剂
DE20019797U1 (de)	2000-11-21	2001-04-05	MALA Verschlußsysteme GmbH, 36448 Schweina	Verschlußkappe
MXPA03005219A (es)	2000-12-12	2003-09-25	Schering Corp	Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
WO2002048157A2 (fr)	2000-12-13	2002-06-20	Bristol-Myers Squibb Pharma Company	Imidazolidinones et leurs derives associes, utiles en tant qu'inhibiteurs des proteases ns3 du virus de l'hepatite c
AU2002230763A1 (en)	2000-12-13	2008-01-03	Bristol-Myers Squibb Pharma Company	Inhibitors of hepatitis c virus ns3 protease
EP1363704A2 (fr)	2000-12-15	2003-11-26	Triangle Pharmaceuticals Inc.	Therapie combinant dabd avec ribavirine ou acide mycophenolique
CA2429352A1 (fr)	2000-12-15	2002-06-20	Lieven Stuyver	Agents antiviraux utilises dans le traitement des infections par les flaviviridae
US6750396B2 (en)	2000-12-15	2004-06-15	Di/Dt, Inc.	I-channel surface-mount connector
US7105499B2 (en) *	2001-01-22	2006-09-12	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
ATE526339T1 (de)	2001-01-22	2011-10-15	Merck Sharp & Dohme	Nukleosidderivate als inhibitoren der rna- abhängigen viralen rna-polymerase
WO2002070533A2 (fr)	2001-03-01	2002-09-12	Pharmasset Ltd.	Procede de synthese de 2',3'-dideoxy-2',3'-didehydronucleosides
GB0112617D0 (en)	2001-05-23	2001-07-18	Hoffmann La Roche	Antiviral nucleoside derivatives
GB0114286D0 (en)	2001-06-12	2001-08-01	Hoffmann La Roche	Nucleoside Derivatives
US6949522B2 (en)	2001-06-22	2005-09-27	Pharmasset, Inc.	β-2′- or 3′-halonucleosides
US6962991B2 (en)	2001-09-12	2005-11-08	Epoch Biosciences, Inc.	Process for the synthesis of pyrazolopyrimidines
WO2003022861A1 (fr)	2001-09-13	2003-03-20	Bristol-Myers Squibb Company	Procede de preparation de rebeccamycine et d'analogues correspondants
WO2003024461A1 (fr)	2001-09-20	2003-03-27	Schering Corporation	Polytherapie de l'hepatite c
EP1435974A4 (fr) *	2001-09-28	2006-09-06	Idenix Cayman Ltd	Procedes et compositions pour le traitement du virus de l'hepatite c au moyen de nucleosides modifies en 4'
GB0129945D0 (en)	2001-12-13	2002-02-06	Mrc Technology Ltd	Chemical compounds
CN100560073C (zh)	2001-12-14	2009-11-18	法玛塞特公司	用于治疗病毒感染的n4-酰基胞嘧啶核苷
AU2002353165A1 (en)	2001-12-17	2003-06-30	Ribapharm Inc.	Deazapurine nucleoside libraries and compounds
WO2003053360A2 (fr)	2001-12-20	2003-07-03	Pharmassett Ltd.	Traitement du virus d'epstein-barr, infection a l'herpesvirus lie au sarcome de kaposi et proliferation cellulaire anormale associee
US20030153744A1 (en)	2001-12-21	2003-08-14	Micrologix Biotech Inc.	Anti-viral 7-deaza L-nucleosides
WO2003062256A1 (fr)	2002-01-17	2003-07-31	Ribapharm Inc.	Analogues d'adenosine 2'-beta-modifiee-6-substituee et leur utilisation en tant qu'agents antiviraux
US7323453B2 (en) *	2002-02-13	2008-01-29	Merck & Co., Inc.	Methods of inhibiting orthopoxvirus replication with nucleoside compounds
EP1485395A4 (fr) *	2002-02-28	2011-04-13	Biota Scient Management	Mimetiques nucleotidiques et leurs promedicaments
US20040023901A1 (en) *	2002-02-28	2004-02-05	Cook Phillip D.	Nucleoside 5'-monophosphate mimics and their prodrugs
AU2003241621A1 (en) *	2002-05-24	2003-12-12	Isis Pharmaceuticals, Inc.	Oligonucleotides having modified nucleoside units
JP2005533777A (ja)	2002-06-17	2005-11-10	メルク　エンド　カムパニー　インコーポレーテッド	Ｒｎａ抗ウイルス剤としての炭素環ヌクレオシドアナログ
AU2003248708A1 (en)	2002-06-17	2003-12-31	Isis Pharmaceuticals, Inc.	Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
US20070004669A1 (en)	2002-06-21	2007-01-04	Carroll Steven S	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
CA2488484A1 (fr)	2002-06-27	2004-01-08	Merck & Co., Inc.	Derives nucleosidiques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale
WO2004002422A2 (fr)	2002-06-28	2004-01-08	Idenix (Cayman) Limited	Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae
CN1761677A (zh)	2002-06-28	2006-04-19	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的修饰的2'和3'－核苷前药
AP2005003211A0 (en)	2002-06-28	2005-03-31	Idenix Cayman Ltd	1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
EP2332952B1 (fr)	2002-06-28	2015-04-29	IDENIX Pharmaceuticals, Inc.	Promédicaments à base de nucléosides modifiés en 2' et 3' pour le traitement d'infections par flavivirus
EP2305257A1 (fr) *	2002-07-08	2011-04-06	ChemGenex Pharmaceuticals, Inc.	Sels d'amonafide et compositions les contenant
AU2003269902A1 (en)	2002-07-16	2004-02-02	Isis Pharmaceuticals, Inc.	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003256619A1 (en)	2002-07-24	2004-02-09	Isis Pharmaceuticals, Inc.	Pyrrolopyrimidine thionucleoside analogs as antivirals
WO2004009610A2 (fr)	2002-07-24	2004-01-29	Ptc Therapeutics, Inc.	Utilisation de composes nucleosidiques pour la suppression non-sens et le traitement de maladies genetiques
CN1671727A (zh)	2002-07-25	2005-09-21	麦克洛基克斯生物技术有限公司	抗病毒7－脱氮－d－核苷及其用途
US20040067877A1 (en)	2002-08-01	2004-04-08	Schinazi Raymond F.	2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
CA2494340C (fr)	2002-08-01	2012-01-24	Pharmasset Inc.	Composes contenant un bicyclo[4.2.1]nonane, utilises dans le traitement des infections causees par les flaviviridae
DE60335805D1 (de)	2002-08-06	2011-03-03	Pharmasset Inc	Verfahren zur herstellung von 1,3-dioxolan-nucleosiden
KR100855907B1 (ko) *	2002-09-13	2008-09-02	노파르티스 아게	내성 ＨＢＶ 균주 치료용 β-Ｌ-2'-데옥시뉴클레오시드 및병용 요법
DK1576138T3 (en)	2002-11-15	2017-05-01	Idenix Pharmaceuticals Llc	2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
AU2003225705A1 (en)	2003-03-07	2004-09-30	Ribapharm Inc.	Cytidine analogs and methods of use
WO2004084453A2 (fr)	2003-03-20	2004-09-30	Microbiologica Quimica E Farmaceutica Ltd.	Procedes de fabrication de 2'-desoxy-$g(b)-l-nucleosides
WO2004096235A2 (fr)	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Analogues de phosphonate anticancereux
US7452901B2 (en) *	2003-04-25	2008-11-18	Gilead Sciences, Inc.	Anti-cancer phosphonate analogs
US20050261237A1 (en)	2003-04-25	2005-11-24	Boojamra Constantine G	Nucleoside phosphonate analogs
JP2006524710A (ja)	2003-04-25	2006-11-02	ギリアードサイエンシーズ，インコーポレイテッド	キナーゼインヒビターホスホネート抱合体
EP2359833A1 (fr)	2003-04-25	2011-08-24	Gilead Sciences, Inc.	Analogues antiviraux du phosphonate
US7168002B2 (en)	2003-04-25	2007-01-23	International Business Machines Corporation	Preservation of error data on a diskless platform
US7407965B2 (en)	2003-04-25	2008-08-05	Gilead Sciences, Inc.	Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) *	2003-04-25	2008-12-30	Gilead Sciences, Inc.	Phosphonate compounds having immuno-modulatory activity
WO2005002626A2 (fr)	2003-04-25	2005-01-13	Gilead Sciences, Inc.	Composes de phosphonate therapeutiques
US20040259934A1 (en)	2003-05-01	2004-12-23	Olsen David B.	Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2005020884A2 (fr)	2003-05-14	2005-03-10	Idenix (Cayman) Limited	Nucleosides pour traitement des infections a coronavirus, a togavirus et a picornavirus
US20040229839A1 (en)	2003-05-14	2004-11-18	Biocryst Pharmaceuticals, Inc.	Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (fr)	2003-05-27	2004-12-09	Syddansk Universitet	Derives de nucleotides fonctionnalises
PT3521297T (pt)	2003-05-30	2022-03-18	Gilead Pharmasset Llc	Análogos de nucleosídeo fluorados modificados
EP1644479A4 (fr)	2003-06-16	2008-04-23	Mark W Grinstaff	Macromolecules et molecules synthetiques fonctionnelles pour l'administration de genes
DE10331239A1 (de)	2003-07-10	2005-02-03	Robert Bosch Gmbh	Überwachungselektronik für einen Elektromotor und Verfahren zur Überwachung eines Elektromotors
US7073213B2 (en)	2003-07-18	2006-07-11	Carlos Duarte	Upright hinge for spa cover
GB0317009D0 (en) *	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
DE602004028841D1 (de)	2003-07-25	2010-10-07	Centre Nat Rech Scient	Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
BRPI0414019A (pt)	2003-08-27	2006-10-24	Biota Inc	nucleosìdios ou nucleotìdio tricìclicos como agentes terapêuticos
US20050148534A1 (en) *	2003-09-22	2005-07-07	Castellino Angelo J.	Small molecule compositions and methods for increasing drug efficiency using compositions thereof
AU2005208887B2 (en)	2004-01-28	2010-02-25	Merck Sharp & Dohme Corp.	Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
WO2005087788A2 (fr)	2004-03-04	2005-09-22	The Regents Of The University Of California	Elaboration de phorphonates-esters nucleosidiques
WO2006000922A2 (fr)	2004-06-23	2006-01-05	Idenix (Cayman) Limited	Derives de 5-aza-7-deazapurine pour le traitement des flaviviridae
CN101023094B (zh)	2004-07-21	2011-05-18	法莫赛特股份有限公司	烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
BRPI0512104A8 (pt)	2004-07-21	2018-04-24	Gilead Pharmasset Llc	preparação de 2-desóxi-2-flúor-d-ribofuranosil pirimidinas substituídas com alquila e purinas e seus derivados
EP1773856B1 (fr)	2004-07-21	2012-02-01	Pharmasset, Inc.	Preparation de pyrimidines et purines 2-desoxy-2-fluoro-d-ribofuranosyl substitues en alkyle et leurs derives
WO2006029081A2 (fr)	2004-09-02	2006-03-16	Neopharm, Inc.	Conjugues nucleoside-lipide, leur procede de preparation, et leurs utilisations
KR101177590B1 (ko) *	2004-09-14	2012-08-27	파마셋 인코포레이티드	2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조
RU2007115419A (ru)	2004-09-24	2008-10-27	Айденикс (Кайман) Лимитед (Ky)	Способы и композиции для лечения флавивирусов, пестивирусов и гепацивируса
US20080280842A1 (en)	2004-10-21	2008-11-13	Merck & Co., Inc.	Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
GB0427123D0 (en)	2004-12-11	2005-01-12	Apv Systems Ltd	Food item coating apparatus and method
CN1827362B (zh)	2005-03-03	2012-01-25	优泊公司	模内成型用标签以及使用该标签的成型品
US20070004299A1 (en)	2005-06-17	2007-01-04	Toray Plastics (America), Inc. Lumirror Division	Barrier film with enhanced adhesive properties
DE102005030372A1 (de)	2005-06-29	2007-01-04	Infineon Technologies Ag	Vorrichtung und Verfahren zur Regelung der Schwellspannung eines Transistors, insbesondere eines Transistors eines Leseverstärkers eines Halbleiter- Speicherbauelements
US7573967B2 (en)	2005-07-01	2009-08-11	Slt Logic Llc	Input threshold adjustment in a synchronous data sampling circuit
US7693225B2 (en)	2005-07-21	2010-04-06	Realtek Semiconductor Corp.	Inter-symbol and inter-carrier interference canceller for multi-carrier modulation receivers
KR20080065272A (ko)	2005-09-26	2008-07-11	파마셋 인코포레이티드	항바이러스제로서의 변형된 4'-뉴클레오시드
KR101238461B1 (ko)	2005-12-09	2013-03-05	길리어드 파마셋 엘엘씨	항바이러스성 뉴클레오시드
DE102005061285A1 (de)	2005-12-20	2007-06-21	Lemförder Electronic GmbH	Wähleinrichtung zum Schalten eines Fahrzeuggetriebes
US8895531B2 (en)	2006-03-23	2014-11-25	Rfs Pharma Llc	2′-fluoronucleoside phosphonates as antiviral agents
PL2084174T3 (pl)	2006-10-10	2013-12-31	Gilead Pharmasset Llc	Sposób otrzymywania nukleozydów rybofuranozylopirymidynowych
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US8286696B2 (en)	2007-06-22	2012-10-16	The Boeing Company	Mechanically actuated thermal switch
CN201113124Y (zh)	2007-07-10	2008-09-10	富士康(昆山)电脑接插件有限公司	电池连接器
US20090318380A1 (en)	2007-11-20	2009-12-24	Pharmasset, Inc.	2',4'-substituted nucleosides as antiviral agents
US20090176732A1 (en)	2007-12-21	2009-07-09	Alios Biopharma Inc.	Protected nucleotide analogs
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
NZ593649A (en)	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Nucleoside analogs
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
EP2376088B1 (fr)	2008-12-23	2017-02-22	Gilead Pharmasset LLC	Phosphoramidates de nucléosides de type 2-amino-purine 6-O-substituée
AR075584A1 (es)	2009-02-27	2011-04-20	Intermune Inc	COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
PT2430014E (pt)	2009-05-13	2015-10-20	Gilead Pharmasset Llc	Compostos antivirais
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
JP2013527145A (ja)	2010-03-31	2013-06-27	ギリード・ファーマセット・エルエルシー	リン含有活性化剤の立体選択的合成
PL2640719T3 (pl)	2010-11-17	2017-10-31	Gilead Pharmasset Llc	Związki przeciwwirusowe
ES2716158T3 (es)	2010-11-30	2019-06-10	Gilead Pharmasset Llc	2'-spiro-nucleótidos para el tratamiento de hepatitis C
US8788437B2 (en)	2011-07-28	2014-07-22	Quova, Inc.	System and method for implementing a learning model for predicting the geographic location of an internet protocol address
MX354958B (es)	2011-09-16	2018-03-27	Gilead Pharmasset Llc	Metodos para el tratamiento de vhc.
DK2635588T3 (en)	2011-11-16	2015-09-07	Gilead Pharmasset Llc	Dehydrated imidazolylimidazoler as anti-viral compounds
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
US20130309196A1 (en)	2012-05-16	2013-11-21	Gilead Sciences, Inc.	Antiviral compounds
US8969588B2 (en)	2012-06-05	2015-03-03	Gilead Pharmasset Llc	Solid forms of an antiviral compound
US9056860B2 (en)	2012-06-05	2015-06-16	Gilead Pharmasset Llc	Synthesis of antiviral compound
US8841340B2 (en)	2012-08-17	2014-09-23	Gilead Sciences, Inc.	Solid forms of an antiviral compound
AR094466A1 (es)	2013-01-14	2015-08-05	Hoffmann La Roche	Proceso para la obtención de un derivado de fluorlactona
WO2015030853A1 (fr)	2013-08-27	2015-03-05	Gilead Pharmasset Llc	Préparation combinée de deux composés antiviraux
TW201609785A (zh)	2013-12-23	2016-03-16	吉李德製藥公司	固體型之抗病毒化合物
TWI679203B (zh)	2014-06-11	2019-12-11	美商基利法瑪席特有限責任公司	製備抗病毒化合物之方法
TWI721947B (zh)	2014-06-11	2021-03-21	美商基利法瑪席特有限責任公司	抗病毒化合物的固態形式

2004
- 2004-04-21 PT PT191604131T patent/PT3521297T/pt unknown
- 2004-04-21 FI FIEP13152340.9T patent/FI2604620T4/fi active
- 2004-04-21 SI SI200432330T patent/SI2604620T2/sl unknown
- 2004-04-21 CA CA2733842A patent/CA2733842A1/fr not_active Abandoned
- 2004-04-21 SI SI200432464T patent/SI1633766T1/sl unknown
- 2004-04-21 SI SI200432518T patent/SI3521297T1/sl unknown
- 2004-04-21 CA CA2734066A patent/CA2734066A1/fr not_active Abandoned
- 2004-04-21 CN CNB2004800191484A patent/CN100503628C/zh not_active Expired - Lifetime
- 2004-04-21 PT PT131523409T patent/PT2604620T/pt unknown
- 2004-04-21 NZ NZ543867A patent/NZ543867A/xx not_active IP Right Cessation
- 2004-04-21 JP JP2006513231A patent/JP4958158B2/ja not_active Expired - Lifetime
- 2004-04-21 KR KR1020057022965A patent/KR100883703B1/ko active IP Right Grant
- 2004-04-21 BR BRPI0410846A patent/BRPI0410846B8/pt active IP Right Grant
- 2004-04-21 EP EP11157942A patent/EP2345658A1/fr not_active Withdrawn
- 2004-04-21 BR BRPI0419345A patent/BRPI0419345B8/pt active IP Right Grant
- 2004-04-21 PL PL13152340.9T patent/PL2604620T5/pl unknown
- 2004-04-21 ES ES13152340.9T patent/ES2586668T3/es not_active Expired - Lifetime
- 2004-04-21 CA CA2734055A patent/CA2734055A1/fr not_active Abandoned
- 2004-04-21 EP EP11157939A patent/EP2345661A1/fr not_active Withdrawn
- 2004-04-21 EP EP21216654.0A patent/EP4032897A1/fr active Pending
- 2004-04-21 EP EP19160413.1A patent/EP3521297B1/fr not_active Expired - Lifetime
- 2004-04-21 HU HUE13152340A patent/HUE029877T2/en unknown
- 2004-04-21 PL PL04775900T patent/PL1633766T3/pl unknown
- 2004-04-21 AU AU2004253860A patent/AU2004253860B2/en not_active Expired
- 2004-04-21 DK DK13152340.9T patent/DK2604620T4/da active
- 2004-04-21 BR BR122018015050-5A patent/BR122018015050B1/pt active IP Right Grant
- 2004-04-21 US US10/828,753 patent/US7429572B2/en active Active
- 2004-04-21 PL PL19160413T patent/PL3521297T3/pl unknown
- 2004-04-21 CA CA2527657A patent/CA2527657C/fr not_active Expired - Lifetime
- 2004-04-21 CA CA2734052A patent/CA2734052A1/fr not_active Abandoned
- 2004-04-21 PT PT04775900T patent/PT1633766T/pt unknown
- 2004-04-21 EP EP04775900.6A patent/EP1633766B1/fr not_active Revoked
- 2004-04-21 ES ES19160413T patent/ES2906207T3/es not_active Expired - Lifetime
- 2004-04-21 ES ES04775900T patent/ES2726998T3/es not_active Expired - Lifetime
- 2004-04-21 EP EP11157954A patent/EP2345659A1/fr not_active Withdrawn
- 2004-04-21 LT LTEP13152340.9T patent/LT2604620T/lt unknown
- 2004-04-21 RU RU2005141176/04A patent/RU2358979C2/ru active
- 2004-04-21 MX MXPA05012788A patent/MXPA05012788A/es active IP Right Grant
- 2004-04-21 TR TR2019/06767T patent/TR201906767T4/tr unknown
- 2004-04-21 WO PCT/US2004/012472 patent/WO2005003147A2/fr active Application Filing
- 2004-04-21 EP EP13152340.9A patent/EP2604620B9/fr not_active Expired - Lifetime
- 2004-04-21 EP EP11157832A patent/EP2345657A1/fr not_active Withdrawn
- 2004-04-28 MY MYPI20041584A patent/MY138477A/en unknown
- 2004-05-07 TW TW093112913A patent/TWI333956B/zh not_active IP Right Cessation
- 2004-05-27 AR ARP040101821A patent/AR044566A1/es not_active Application Discontinuation
2005
- 2005-11-24 ZA ZA200509521A patent/ZA200509521B/en unknown
- 2005-11-29 IL IL172259A patent/IL172259A/en active IP Right Grant
- 2005-12-05 CO CO05123296A patent/CO5660270A2/es active IP Right Grant
- 2005-12-28 NO NO20056221A patent/NO333700B1/no unknown
2007
- 2007-09-12 US US11/854,218 patent/US10287311B2/en active Active
2008
- 2008-06-19 US US12/142,554 patent/US20080253995A1/en not_active Abandoned
- 2008-06-19 US US12/142,536 patent/US20090004135A1/en not_active Abandoned
- 2008-09-29 US US12/240,342 patent/US20090036666A1/en not_active Abandoned
2010
- 2010-09-09 US US12/878,262 patent/US8415322B2/en not_active Expired - Lifetime
- 2010-12-29 IL IL210367A patent/IL210367A0/en active IP Right Grant
2011
- 2011-04-11 NO NO20110547A patent/NO20110547L/no not_active Application Discontinuation
- 2011-04-11 NO NO20110550A patent/NO20110550L/no not_active Application Discontinuation
- 2011-04-11 NO NO20110548A patent/NO20110548L/no unknown
- 2011-04-11 NO NO20110549A patent/NO20110549L/no not_active Application Discontinuation
- 2011-04-14 JP JP2011090084A patent/JP2011201882A/ja not_active Withdrawn
- 2011-04-14 JP JP2011090076A patent/JP2011190264A/ja not_active Withdrawn
- 2011-04-14 JP JP2011090062A patent/JP2011190263A/ja not_active Withdrawn
- 2011-04-14 JP JP2011090054A patent/JP5266357B2/ja not_active Expired - Lifetime
- 2011-06-30 AR ARP110102357A patent/AR082067A2/es unknown
- 2011-06-30 AR ARP110102358A patent/AR082068A2/es unknown
- 2011-06-30 AR ARP110102356A patent/AR082066A2/es unknown
- 2011-06-30 AR ARP110102354A patent/AR082064A2/es unknown
2012
- 2012-06-07 US US13/491,441 patent/US20120245335A1/en not_active Abandoned
2016
- 2016-07-14 HR HRP20160873TT patent/HRP20160873T4/hr unknown
- 2016-09-19 CY CY20161100927T patent/CY1118020T1/el unknown
- 2016-12-21 LT LTPA2016046C patent/LTPA2016046I1/lt unknown
- 2016-12-21 HU HUS1600062C patent/HUS1600062I1/hu unknown
- 2016-12-22 CY CY2016052C patent/CY2016052I1/el unknown
2018
- 2018-06-26 AR ARP180101768A patent/AR114929A2/es not_active Application Discontinuation
- 2018-10-17 US US16/162,634 patent/US20190315792A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUS1600062I1 (hu)	2017-01-30
US20080070861A1 (en)	2008-03-20
NZ543867A (en)	2009-05-31
CO5660270A2 (es)	2006-07-31
JP2011190264A (ja)	2011-09-29
DK2604620T4 (da)	2024-09-16
BRPI0419345B1 (pt)	2020-12-22
EP2604620B1 (fr)	2016-06-29
KR100883703B1 (ko)	2009-02-12
EP1633766B1 (fr)	2019-03-06
US20120245335A1 (en)	2012-09-27
EP2604620B9 (fr)	2024-10-23
CA2527657A1 (fr)	2005-01-13
EP3521297A1 (fr)	2019-08-07
JP2006526629A (ja)	2006-11-24
EP2604620B2 (fr)	2024-06-19
ES2906207T3 (es)	2022-04-13
LTPA2016046I1 (lt)	2017-01-10
MXPA05012788A (es)	2006-02-22
SI1633766T1 (sl)	2019-06-28
PL2604620T5 (pl)	2024-10-14
JP5266357B2 (ja)	2013-08-21
MY138477A (en)	2009-06-30
AU2004253860A2 (en)	2005-01-13
EP2345659A1 (fr)	2011-07-20
IL172259A (en)	2010-12-30
HRP20160873T1 (hr)	2016-09-23
US20110038833A1 (en)	2011-02-17
US20090004135A1 (en)	2009-01-01
US7429572B2 (en)	2008-09-30
PL1633766T3 (pl)	2019-09-30
NO20110548L (no)	2005-12-28
EP2345658A1 (fr)	2011-07-20
EP3521297B1 (fr)	2021-12-22
DK2604620T3 (en)	2016-10-03
JP2011201882A (ja)	2011-10-13
AR082066A2 (es)	2012-11-07
BR122018015050B1 (pt)	2021-07-13
WO2005003147A3 (fr)	2005-03-03
US20080253995A1 (en)	2008-10-16
TWI333956B (en)	2010-12-01
RU2005141176A (ru)	2006-06-27
US20050009737A1 (en)	2005-01-13
JP2011178795A (ja)	2011-09-15
PL3521297T3 (pl)	2022-04-04
ES2726998T3 (es)	2019-10-11
AR082064A2 (es)	2012-11-07
PT1633766T (pt)	2019-06-04
NO20110550L (no)	2005-12-28
KR20060020649A (ko)	2006-03-06
SI2604620T1 (sl)	2016-10-28
NO20056221L (no)	2005-12-28
EP2604620A1 (fr)	2013-06-19
CA2527657C (fr)	2011-06-14
US10287311B2 (en)	2019-05-14
NO333700B1 (no)	2013-08-26
CY2016052I2 (el)	2017-07-12
AR082068A2 (es)	2012-11-07
HRP20160873T4 (hr)	2024-10-11
US8415322B2 (en)	2013-04-09
CN1816558A (zh)	2006-08-09
EP2345661A1 (fr)	2011-07-20
CA2734055A1 (fr)	2005-01-13
LT2604620T (lt)	2016-09-12
CA2734066A1 (fr)	2005-01-13
TR201906767T4 (tr)	2019-05-21
PT2604620T (pt)	2016-08-18
PT3521297T (pt)	2022-03-18
JP2011190263A (ja)	2011-09-29
JP4958158B2 (ja)	2012-06-20
EP4032897A1 (fr)	2022-07-27
WO2005003147A2 (fr)	2005-01-13
CY2016052I1 (el)	2017-07-12
US20190315792A1 (en)	2019-10-17
BRPI0410846B1 (pt)	2019-01-15
SI2604620T2 (sl)	2024-10-30
BRPI0410846A (pt)	2006-06-27
US20090036666A1 (en)	2009-02-05
EP2345657A1 (fr)	2011-07-20
NO20110549L (no)	2005-12-28
BRPI0410846B8 (pt)	2021-05-25
EP1633766A2 (fr)	2006-03-15
FI2604620T4 (fi)	2024-09-11
SI3521297T1 (sl)	2022-04-29
RU2358979C2 (ru)	2009-06-20
CA2733842A1 (fr)	2005-01-13
ES2586668T3 (es)	2016-10-18
AU2004253860A1 (en)	2005-01-13
AR082067A2 (es)	2012-11-07
CN100503628C (zh)	2009-06-24
AU2004253860B2 (en)	2009-06-11
PL2604620T3 (pl)	2016-12-30
NO20110547L (no)	2005-12-28
CY1118020T1 (el)	2017-05-17
AR114929A2 (es)	2020-11-11
BRPI0419345B8 (pt)	2021-05-25
AR044566A1 (es)	2005-09-21
HUE029877T2 (en)	2017-04-28
CA2734052A1 (fr)	2005-01-13
IL210367A0 (en)	2011-03-31
TW200510445A (en)	2005-03-16